Citations Citations to this article as recorded by Diabetes Fact Sheet 2025: Special Edition on Diabetes with Obesity and in Pregnancy Se Eun Park, Se Hee Min, Jin Hwa Kim, Seung-Hwan Lee, Han Na Jung, Joon Ho Moon, Kyungdo Han, Seung-Hyun Ko, Bong Soo Cha, Sung Hee Choi Diabetes & Metabolism Journal.2026
Shifting your injection window by 612 hours week to week doesn't break the protocol, but it introduces unnecessary plasma level fluctuation that can amplify side effects
In people with type 2 diabetes, retatrutide reduced HbA1c by 2.2% after 36 weeks
For the full regulatory picture, see FDA peptide crackdown 2026
Our apologies
Tirzepatide carries a boxed warning for risk of thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2)